This trial is active, not recruiting.

Condition liver cancer, lung cancer, pancreatic cancer
Sponsor Duke University
Start date November 2011
End date August 2015
Trial size 25 participants
Trial identifier NCT02019199, Pro00032595


This study is a research initiative established to explore the use of magnetic resonance imaging (MRI) as a tool for detecting organ motion as it pertains to planning radiation therapy.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Primary Outcomes

To evaluate the accuracy, robustness, and efficacy of MRI for tumor motion measurement.
time frame: During MRI approx 1 hour
Tumor volume
time frame: During MRI approx 1 hour
Tumor contrast-to-noise ratio (CNR)
time frame: During MRI approx 1 hour
Tumor Motion
time frame: During MRI approx 1 hour

Eligibility Criteria

Male or female participants at least 21 years old.

Inclusion Criteria: - Age ≥ 21 - Patients with primary or metastatic tumors in the lungs, liver, or pancreas - Patients undergoing a planning CT scan in the Department of Radiation Oncology with tumor motion assessment - planning 4D-CT ordered by the treating Radiation Oncologist - Signed, specific informed consent prior to study entry Exclusion Criteria: - Any condition for which a MRI procedure is contraindicated including presence of metallic material in the body, such as pacemakers, non- MRI compatible surgical clips, shrapnel, etc - Pregnant or breast-feeding women - Subjects who have difficulty lying flat on their back for extended periods of time

Additional Information

Official title Magnetic Resonance Imaging ( MRI) for Radiation Therapy Treatment Planning Evaluation of Lung, Liver and Pancreatic Motion.
Principal investigator Brian Czito, MD
Description The goal with radiation therapy is to treat the defined tumor and spare the surrounding normal tissue from receiving dose above specified tolerance doses. There is evidence of improved local control and survival with higher doses of radiation, however, at the same time there is the need to spare normal tissues from higher doses of radiation. Technologies that allow the delivery of an increased radiation dose to the tumor while sparing normal tissue have the potential of improving the therapeutic ratio. However, the development of these technologies has been hampered by organ respiratory motion particularly in the case of the lungs and liver. Inadequate radiation coverage of a tumor secondary to organ motion can lead to delivering a lower dose to a portion of the tumor. Making the field of radiation larger to account for organ motion results in unnecessary radiation dose to surrounding healthy tissues. It is therefore desirable to document the extent of motion of the organ in question prior to carrying out the radiation treatment planning. The organ motion impacts directly on the radiation dose distribution in the treatment volume.
Trial information was received from ClinicalTrials.gov and was last updated in November 2016.
Information provided to ClinicalTrials.gov by Duke University.
Location data was received from the National Cancer Institute and was last updated in August 2016.